Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive Reported Operating Profit
Takeda Named Global Top Employer for Third Year Running
SEE ALL NEWS AND RELEASES >
・For legacy Shire information, click here
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2020 Takeda Pharmaceutical Company Limited. All rights reserved.